Commissioners have a statutory responsibility to make funding available for a drug or treatment recommended by a NICE TA and to begin doing so no later than 90 calendar days (30 calendar days for cancer medicines) after the guidance is published, unless otherwise specified in the guidance. Compliance is achieved when a patient, after discussion with a clinician, is able to choose a NICE-recommended treatment without any local funding or formulary restrictions.

For the avoidance of doubt, when NICE recommends a drug as 'an option', this is an option for the clinician and patient to consider alongside other potential treatments, not an option for commissioners or providers to not make the treatment available.